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Frontotemporal dementia (FTD) is the second most prevalent form of early onset dementia
after Alzheimer’s disease (AD). We performed a case-control association study in an Italian FTD cohort
(n ¼ 530) followed by the novel single nucleotide polymorphisms (SNPs)-to-genes approach and
functional annotation analysis. We identiﬁed 2 novel potential loci for FTD. Suggestive SNPs reached
p-values w107 and odds ratio > 2.5 (2p16.3) and 1.5 (17q25.3). Suggestive alleles at 17q25.3 iden-
tiﬁed a disease-associated haplotype causing decreased expression of ecis genes such as RFNG and
AATK involved in neuronal genesis and differentiation and axon outgrowth, respectively. We repli-
cated this locus through the SNPs-to-genes approach. Our functional annotation analysis indicated
signiﬁcant enrichment for functions of the brain (neuronal genesis, differentiation, and maturation),ar Neuroscience, Institute of
een Square, London, WC1N
Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Populationthe synapse (neurotransmission and synapse plasticity), and elements of the immune system, the
latter supporting our recent international FTDegenome-wide association study. This is the largest
genome-wide study in Italian FTD to date. Although our results are not conclusive, we set the basis for
future replication studies and identiﬁcation of susceptible molecular mechanisms involved in FTD
pathogenesis.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Frontotemporal dementia (FTD) is the second most prevalent
form of early onset dementia after Alzheimer’s disease (AD),
worldwide (Ratnavalli et al., 2002). The 2 main FTD syndromes
affect an individual’s behavior or language resulting either in the
behavioral variant FTD (bvFTD) or the language variant broadly
named primary progressive aphasia (PPA) (Gorno-Tempini et al.,
2011; Rascovsky et al., 2011). The latter is subdivided into seman-
tic variant PPA and non-ﬂuent/agrammatic variant PPA (Gorno-
Tempini et al., 2011). Each of these syndromes is distinct and is
characterized by speciﬁc signatures (Ferrari et al., 2013). FTD can
also overlap with motor neuron disease (MND) resulting in the
broad subgroup called FTD-MND (Strong et al., 2009).
The genetics of FTD have become clearer over the past 15 years
whenmutations in themicrotubuleassociatedprotein tau (MAPT) and
progranulin (GRN) genes were identiﬁed (Baker et al., 2006; Cruts
et al., 2006; Hutton et al., 1998); more recently, a repeat expansion
in theC9orf72genehasbeen reported in the FTDeamyotrophic lateral
sclerosis spectrum (DeJesus-Hernandez et al., 2011; Renton et al.,
2001) and a small number of FTD cases (<5% all together) has been
associated with variability in a handful of genes including the
transactive response DNA binding protein 43 (TDP-43) and valosin
containing protein (Ferrari et al., 2013; Rohrer and Warren, 2011).
Recently, international genome-wide association studies (GWAS)
identiﬁed novel potential risk factors for FTD with TDP-43 pathology
such as the transmembrane protein 106B (TMEM106B) gene (Van
Deerlin et al., 2010), and the locus containing the RAB38, member
RAS oncogene family (RAB38) and catepsin C (CTSC) genes for bvFTD,
and the HLA locus for the FTD spectrum (Ferrari et al., 2014).
Currently, there are no comprehensive epidemiological data on
monogenic FTD in the Italian population. However, the majority of
FTD cases has been associated with GRN mutations (Benussi et al.,
2009; Borroni et al., 2011), whilst only a few cases with MAPT
(Alberici et al., 2004; Binetti et al., 2003). In addition, a few cases
have been associatedwithmutations inTDP-43 (Borroni et al., 2010)
and no proper epidemiological data yet exist on C9orf72 variants
(Benussi et al., 2014; Galimberti et al., 2014; Ticozzi et al., 2014). For
the vast majority of cases in Italy, the common genetic un-
derpinnings of the disease are still unknown.
As we had access to genome-wide genotyping data for > 600
Italian FTD cases, we intended to better characterize the genetic
underpinnings of FTD in this population. Here, we present the re-
sults of our analysis of genome-wide markers in the classical as-
sociation and the novel SNPs-to-genes fashions. In addition, we also
performed functional annotation of the suggestive genes that we
identiﬁed.2. Materials and methods
2.1. Samples
2.1.1. Cases
Genotyping data of DNA samples diagnosed with FTD were
available to us from the FTD-GWAS data set (Ferrari et al., 2014);speciﬁcally, we had access to raw data of 634 samples, which were
obtained from 8 Italian research centers (Supplementary Table 8).
After quality check (QC) steps 530 patients diagnosed with bvFTD
(n ¼ 418), semantic variant PPA (n ¼ 27), agrammatic variant PPA
(n ¼ 61), and FTD-MND (n ¼ 23) were included in the study. Mean
( standard deviation [SD]) age of onset was 64.1  20.7 years
(range, 29.0e87.0) with male-to-female ratio 243/287. Four hun-
dred eighty-two of 530 cases had been characterized for candidate
genes: a minority of cases carried variants in MAPT (n ¼ 2; 0.4%),
GRN (n¼ 37; 7.7%), and C9orf72 (n¼ 27; 5.6%). Three cases (2 bvFTD
and 1 FTD-MND) had double variants (C9orf72 and GRN). The cases
with variants in MAPT and GRN were kept in the study because
these were nonpathogenic polymorphisms. Conversely, all cases
with known pathogenic mutations inMAPT and GRNwere excluded
from the study a priori, whereas those carrying C9orf72 expansions
were kept because we adopted here the same strategy as in the
international FTD-GWAS (Ferrari et al., 2014). All cases were diag-
nosed according to the Neary criteria (Neary et al., 1998) and/or the
more recent Rascovsky and Gorno-Tempini criteria (Gorno-Tempini
et al., 2011; Rascovsky et al., 2011). The cases were collected and
genotyped at the University College London by means of Illumina
human 660K-Quad Beadchips assayed on the Illumina Inﬁnium
platform (Illumina, San Diego, CA, USA).
2.1.2. Controls
The control sample used in the present study has been collected
during the HYPERGENES project (European Network for Genetic-
Epidemiological Studies; www.hypergenes.eu) (Salvi et al., 2012).
The sample set (n ¼ 1327; 926 after QC) included 349 (37.7%)
women and the mean (SD) age was 58.2  6.1 years (range,
50.0e97.0). All participants were unrelated, collected in Italy, and of
Caucasian ancestry. All subjects had no abnormal ﬁndings on
physical and neurological examination. The control samples were
genotyped at the University of Milan, using the Illumina 1M-duo
array.
Written informed consent from patients and control individuals
was obtained at every site by the principal investigator. Each study
site obtained approval from a local ethics committee (UK ethics
committee number 10/H0716/3, ethics committee of the University
of Milan approval 24/04/2008) or institutional research board;
every participating group provided consent for the use of the
samples to pursue the goals of this study.2.2. Association and expression quantitative trait loci analyses
All QC steps were performed in accordance with the protocol
written by C.A Anderson (Anderson et al., 2010).
We assessed population structure using principal components
analysis (PCA) as implemented in the Golden Helix software (http://
www.goldenhelix.com/) to infer continuous axes of genetic varia-
tion. We ruled out relatedness across subjects (cases and controls)
through identity-by-descent analysis, as implemented in PLINK, for
all possible pairs of individuals. After these QC steps, we found that
none of the cases and controls were related. We excluded outlier
samples deﬁned as individuals exceeding a default number of SDs
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quality to impute approximately 2.5 million SNPs, based on
European-ancestry haplotype reference (HapMap II CEU population
build 36, release 22). Imputed SNPs with a minor allele frequency
(MAF) < 0.01 and with low imputation quality (Rsq < 0.80) were
removed. We then computed each SNP p value with a logistic
regression of FTD status on SNP dosage levels, adjusting for sex, and
the ﬁrst 4 principal components. Imputation and single-marker
signiﬁcance were performed using mach2dat software (Li et al.,
2010).
Three polymorphisms (rs17650901, rs1052553, and rs17652121)
throughout the MAPT gene are in complete linkage disequilibrium
with each other and are inherited as 2 separate haplotypes, H1 and
H2. For each sample, we constructed the MAPT haplotypes and we
performed case and/or control haplotype associations to test for
association with disease. The logistic regressions are corrected for
sex and the ﬁrst 4 principal components.
Suggestive SNPs were investigated for potential effects on
expression quantitative trait loci in brain using the online freely
available database braineac (http://www.braineac.org/; accessed in
December 2014). This data set allows identiﬁcation of effects in cis
only (1 Mb from each SNP of interest). The signiﬁcance threshold
is p-value  105, as recommended by the database curators.
We also used in the GenomeStudio data analysis software
(Illumina) to perform loss of heterozygosity and copy number
variant (CNV) analysis for the suggestive loci: we evaluated the
LogR ratio and B Allele Frequency and visualized CNVs within the
chromosomal browser heat map in GenomeStudio.
2.3. SNPs-to-genes analysis
To map the SNPs-to-genes, containing genomic coordinates for
all genes according to positions on the Genome Browser, hg18 (NCBI
assembly GRCh36) were downloaded from the PLINK ftp server
[http://pngu.mgh.harvard.edu/wpurcell/plink/res.shtml#hapmap]
(accessed in September 2014). SNPs were assigned to a gene if they
located within its primary transcript (intragenic region) or 5 kilo-
bases (kb) upstream or downstream of the gene start or end. This
was done based on the following reasons: (1) small windows pre-
vent the assignment of an SNP tomultiple genes because of reduced
overlap of ﬂanking regions; (2) a small percentage of SNPs beyond
10 kb are in moderate to high linkage disequilibrium (LD) with the
SNPs within a gene (Petersen et al., 2013); (3) adding SNPs mapped
farther away from a gene (20 kb) will include noncausal SNPs and
increment noise signals that will eventually impact the power of
gene-based tests (Petersen et al., 2013). In total, 965,052 SNPs (42%
of the 2,292,247 SNPs of the SNPs imputed during association
analysis) were assigned to 18,011 protein coding genes (95.5% of the
18,867 of the PLINK list).
We used an innovative approach to investigate these data by
means of 3 different gene-based statistical methods: (1) the
extended Simes’ procedure (GATES) with SNP pruning based on
MAF >0.01; (2) the supervised PCA (sPCA) test with SNP pruning
based on MAF >0.01 and SNP log-likelihood > 75%, and; (3) the
sequential kernel machine association test (SKAT) without SNP
pruning. The p values of our genome-wide classical association
analysis as well as raw genotyping data were used to perform these
analyses.
The GATES method (Li et al., 2011) is an extension of the Simes’
approach (Simes, 1986) that combines multiple single marker
genotype-phenotype tests (p values) applied to each SNP. Brieﬂy, a
gene-representative p value is derived from the SNP p values of the
primary association analysis using effective numbers of indepen-
dent SNP p values. In this fashion the gene p values are combined to
control for the SNP correlation structure that is estimated by thepairwise LD between the SNPs computed on the current cohort
under study. An advantage of GATES is that if only SNP-based
p values are accessible, LD information from a known reference
population (e.g., HapMap) can be used to account for the absence of
individual genotype information. Thus, GATES is a meta-analysis
(post GWAS) method that does not require raw individual pheno-
type and genotyping data.
The sPCA method (Bair et al., 2006) combines the SNPs that fall
within the gene set, based on the genotype calls; then instead of
performing PCA (Ma and Dai, 2011) on all SNPs within the gene,
estimated PCs are calculated from a subset of SNPs. Because the
subset of SNPs is selected using outcome (case-control status) in-
formation, it is a supervised procedure. The assumption behind the
sPCA is that given a priori deﬁned group of SNPs, only a subset of
these SNPs is associated with a latent variable, which then varies
with outcome. sPCA uses the ﬁrst PC score (PC1), also called
“eigengene”, to estimate the latent variable. Subsequently, the
p value of the PC1 effect in a logistic regression evaluates the as-
sociation between the eigengene and disease outcome.We used the
likelihood percentile ﬁlter with a threshold of 75% as an SNP
pruning method (Spencer et al., 2014). This ranks the log-likelihood
values, from a univariate logistic model with case-control status as
outcome and SNP status as predictor and ﬁlters a prespeciﬁed
number or proportion of SNPs, that is, our threshold of 75% retains
the top ranked 25% of SNPs.
The SKAT approach (Wu et al., 2010) is a regression method
to test for association between genetic variants (common and
rare) in a region. It considers a logistic kernel-machine model
(Liu et al., 2008) for the joint effect of the SNPs in the gene set.
The SNPs inﬂuence outcome through a general nonlinear kernel
function K(S, S), which is an arbitrary function that measures
the genomic similarity between the genotypes of the SNPs in
the gene set and disease risk. Some commonly used kernels
include linear, identity-by-descent and quadratic kernels. Many
genotyped SNPs and rare variants (MAF < 0.01) are correlated,
and thus the logistic kernel-machine test has good power to
detect a signiﬁcant gene-set effect without an initial pruning.
Treating K(S, S) as subject-speciﬁc random effects, SKAT uses a
score-based variance-component test (with only 1 degree of
freedom) to evaluate association between the SNPs in the gene
set and the case-control status. We set K(S, S) as the linear
kernel to calculate p values analytically, thus SKAT can easily be
applied to analyse genome-wide data.
Once nominal gene p values are obtained from GATES, sPCA and
SKAT, we next calculate adjusted p values to control for false dis-
covery rate (FDR) using Benjamini and Hochberg (Benjamini and
Hochberg, 1995) correction procedure. The signiﬁcance cutoff
level of p < 0.05 was used.
To implement the pipeline analysis, we developed our own
custom codes of the R v3.1.2 software (www.r-project.org/) by using
the R packages SNPRelate, postgwas, spc, assotestR, multtest for
read PLINK GWAS ﬁles, compute LD, perform GATES, sPCA, and
SKAT analysis, and list adjusted p values, respectively.
2.4. Gene ontology analysis
To assess the biological relevance of the suggestive genes iden-
tiﬁed through the association and the SNPs-to-genes analyses,
functional annotation analysis of gene ontology (GO) terms
(Ashburner et al., 2000) was performed.
First, a list of disease-associated genes (DAGs) (see
Supplementary Table 4; Supplementary Fig. 4g), including sugges-
tive genes as per association analysis with p-value< 104and genes
derived from the GATES þ sPCA þ SKAT analyses with p-value < 0.1
(after FDR correction), was selected and processed by means of
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Discovery) (Huang da et al., 2009) for functional annotation clus-
tering, considering all GO categories (molecular function [MF],
biological process [BP], and cellular component [CC]). DAVID used
an agreement score (kappa statistics) matrix and a fuzzy heuristic
algorithm (Huang et al., 2007) to cluster functionally similar GO
terms associated with DAGs into groups. The highest clustering
stringency was used, as this generates fewer functional groups with
stronger association between the genes included in each group. An
“enriched” p value was assigned to each term by comparing the
selected gene list to the whole human genome by a modiﬁed
Fisher’s exact test. For each cluster an enrichment score
(ES) ¼ log10 (geometric mean of the term p values in the cluster)
was computed, and the clusters with an ES  1.3 or greater were
highlighted, as this is equivalent to nonlog scale of p value of
101.3 ¼ 0.05.
Second, accounting for the hierarchical (parent-child) structure
of GO, and to reduce redundancy, we performed a gene-set
enrichment analysis for each GO category (BP, CC, and MF) using
the Kolmogorov-Smirnov test as implemented in Alexa et al.
(2006). This ranks all the p values of the gene-based analysis and
then tests an ES based on the maximum ranking deviation of the
genes annotated in a GO term from a random gene set uniformly
distributed, as expected by chance. This was done for all GO terms.
We used gene p value as the minimum p value from the GATES,
sPCA, or SKAT p values. In addition, we selected the option
“weight01”, a GO term decorrelation, which considers only the best
ﬁtted GO-term, removing redundancy between reported terms.
Speciﬁcally, weight01 method is a heuristic combination of “elim”
and “weight” methods. The former investigates the GO nodes from
the bottom to the top of the GO hierarchy to ensure that the most
speciﬁc nodes are scored, and iteratively removes the genes map-
ped to signiﬁcant GO terms before scoring the parent nodes. The
latter investigates the GO nodes bottom up such as the elimmethod
but, instead of removing the genes once a signiﬁcant node has been
scored, it assigns weights based on the scores of neighboring GO
terms to each gene.
As for the gene-based pipeline, GO analysis was performed by
our own custom R codes with packages RDAVIDWebService, and
topGO for DAVID clustering, and gene set enrichment analysis,
respectively.
3. Results
3.1. Association and expression quantitative trait loci analyses
Our association analysis was performed on 530 FTD cases and
926 controls. We did analyze the entire cohort, whereas we could
not analyze each subtype separately because of statistical power
issues.
3.1.1. Analysis of novel genetic markers
We did not identify SNPs that reached the genome-wide sig-
niﬁcance level (p-value < 2.18  108). However, considering as
suggestive threshold the p-value  105 (Supplementary Table 1),
as supported by the quantile-quantile plot (Supplementary Fig. 1), a
number of SNPs mapping to chromosomes (chr) 2 and 17 were
strongly suggestive (Table 1; Fig. 1).
All suggestive SNPs mapping to the short arm of chr 2 (2p16.3
locus) located to introns of the uncharacterized gene LOC730100
(Fig. 2A). For each suggestive SNP the minor alleles showed odds
ratios (OR) exceeding 2.5 (Table 1). Regional plot analysis at this
locus (Fig. 2B) revealed that the SNPs clustering within
LOC730100 are in strong LD with each other but not with any
surrounding SNP (0.5 Mb centromeric and 3 Mb telomeric)suggesting high rates of recombination at this locus. We evalu-
ated effects on transcription exerted by the suggestive SNPs at
the 2p16.3 locus: data were only available for the risk allele of
rs12619513 (LOC730100), revealing no signiﬁcant in cis effects on
transcription in any of the assayed brain tissues (Supplementary
Table 2). LOC730100 is immediately located downstream
(centromeric) from the neurexin 1 (NRXN1) gene (Fig. 2A); based
on our data, no SNPs within NRXN1 resulted signiﬁcant or sug-
gestive neither they were in LD with the suggestive SNPs found in
LOC730100. NRXN1 is involved in neurodevelopment and it was
shown being polymorphic, especially, carrying CNVs associated
with a spectrum of neurobehavioral and neuropsychiatric disor-
ders (Bena et al., 2013). The visual analysis of the distribution of
the SNPs at the NRXN1 locus through the Illumina Genome
Viewer in GS did not provide evidence for CNVs within NRXN1 in
our sample set; of note, when the B allele frequency plot sug-
gested the possibility of a CNV this was not supported by the
LogR ratio plot (see 2 examples in Supplementary Fig. 2a and 2b).
The suggestive SNPs mapping to the long arm of chr 17
(17q25.3locus) located to the introns of 2 genes, the centrosomal
protein 131 (CEP131) and the yet uncharacterized C17orf89, and to
the 30-UTR of the ENTH domain containing 2 (ENTHD2) gene
(Fig. 2C). The OR for the risk alleles barely exceeded 1.5 (Table 1).
Regional plot analysis at this locus revealed that 12 SNPs
(rs906175, rs2659030, rs9912789, rs9896850, rs2725391,
rs9319617, rs12939525, rs8073077, rs969413, rs1048775,
rs2255166, and rs2659005) spanning a genetic region ofw45.2 Kb
comprising the CEP131, ENTHD2, and C17orf89 genes are in mod-
erate to strong LD (Fig. 2D; Table 2), suggesting that a haplotype
substructure at this locus might associate with the disease in this
population. Our haplotype analysis showed that either in the case
of the 12 SNPs in LD (rs906175, rs2659030, rs9912789, rs996850,
rs2725391, rs9319617, rs12939525, rs8073077, rs969413,
rs1048775, rs2255166, and rs2659005) or the 7 SNPs highlighted
by our association analysis (rs906175, rs2725391, rs969413,
rs2659030, rs2255166, rs9319617, and rs1048775) there was: (1) a
risk haplotype substructure suggestive of association with dis-
ease: TACCTTTCACCT with p-value ¼ 1.60  105 and OR ¼ 1.42,
and TATACTC with p-value ¼ 4.39  106 and OR ¼ 1.45, respec-
tively (Table 2), and; (2) a protective haplotype substructure
suggestive of association with the controls: CGTTCCCTTGTC with
p-value ¼ 7.42  106 and OR ¼ 0.695, and CGCTGCT with
p-value ¼ 8.30  107 and OR ¼ 0.67, respectively (Table 2). We
then analyzed the potential effects exerted on transcription by the
suggestive SNPs (rs906175, rs2725391, rs969413, rs2659030,
rs2255166, rs9319617, and rs1048775) at this locus: signiﬁcant
inecis effect was seen for rs906175 (risk allele T; p-value ¼ 5.6 
106) and rs2659030 (risk allele A; p-value ¼ 7.7  106) both
associating with decreased expression of the radical fringe (RFNG)
gene in the hippocampus (Supplementary Table 3; Supplementary
Fig. 3a). Other 4 SNPs (rs2725391, rs969413, rs2255166, and
rs9319617) showed that their risk alleles were suggestive for
inecis effects also on decreased expression of RFNG in the hip-
pocampus (Supplementary Table 3). Six SNPs (rs906175,
rs2725391, rs969413, rs2659030, rs9319617, and rs1048775)
showed that their risk alleles had suggestive effects on decreased
expression of the apoptosis-associated tyrosine kinase (AATK)
gene and the microRNA 1250 (MIR1250) in the temporal cortex
(Supplementary Table 3; Supplementary Fig. 3b). Taken together,
these data are of relevance for a number of reasons: (1) they reveal
a suggestive risk haplotype on chr 17 encompassing the 3 genes
CEP131, ENTHD2, and C17orf89 in our cohort, and; (2) each of the
suggestive SNPs affects transcription inecis: particularly, all the
risk alleles of the suggestive SNPs cause a regional-speciﬁc
decrease in expression of the cis genes RFNG (hippocampus) and
Fig. 1. Manhattan plot of the association analysis. The genome-wide signiﬁcance level threshold was: p-value ¼ 2.18  108. Single nucleotide polymorphisms on chromosomes 2
and 17 reached strongly suggestive p values. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
Table 1
Genome-wide association results for FTD-associated SNPs with p-value < 106
Marker Chromosome Position
(bp)
Nearest gene Location Minor
allele
Major
allele
Frequency of minor
allele
Imputation
quality (Rsq)
OR of minor
allele (95% CI)
p Value
rs906175 17 79,173,462 CEP131 Intron 9 T C 0.48 0.88 1.58 (1.33e1.87) 1.22  107
rs17042852 2 52,600,067 LOC730100 Intron 10 C T 0.04 0.97 2.82 (1.91e4.18) 2.01  107
rs1526678 2 52,635,727 LOC730100 intergenic G A 0.04 0.99 2.83 (1.91e4.20) 2.19  107
rs17042770 2 52,571,393 LOC730100 Intron 8 C G 0.04 0.96 2.83 (1.91e4.20) 2.22  107
rs2725391 17 79,192,430 CEP131 Intron 2 T C 0.48 0.98 1.52 (1.30e1.78) 2.50  107
rs12621157 2 52,509,876 LOC730100 Intron 7 T G 0.04 0.96 2.75 (1.87e4.07) 3.73  107
rs12622570 2 52,546,301 LOC730100 Intron 8 C G 0.04 0.96 2.76 (1.87e4.09) 3.99  107
rs969413 17 79,195,814 CEP131 Intron 1 A T 0.49 0.95 1.52 (1.29e1.79) 4.26  107
rs2659030 17 79,177,974 CEP131 Intron 5 A G 0.46 0.83 1.56 (1.31e1.86) 4.42  107
rs2255166 17 79,213,562 C17orf89 Intron 2 C T 0.46 0.85 1.55 (1.30e1.84) 6.19  107
rs12619513 2 52,532,874 LOC730100 Intron 7 A G 0.05 0.94 2.53 (1.76e3.65) 6.39  107
rs9319617 17 79,192,446 CEP131 Intron 2 C T 0.48 0.97 0.66 (0.57e0.78) 6.62  107
rs1048775 17 79,202,329 ENTHD2 30-UTR G C 0.50 0.91 0.66 (0.56e0.78) 8.04  107
rs12614311 2 52,521,716 LOC730100 Intron 7 T C 0.06 0.81 2.55 (1.75e3.71) 8.83  107
To retrieve information about SNPs and their genomic context (the nearest gene and location) we used the hg18 (NCBI 36) assembly. We performed a logistic regression of FTD
status on SNP dosage levels adjusting for sex and the ﬁrst 4 principal components. The SNPs are ranked by p value.
Key: CI, conﬁdence interval; FTD, frontotemporal dementia; OR, odds ratio; SNPs, single nucleotide polymorphisms.
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Fig. 2. Suggestive loci and regional plot analysis. (A) Highlight of the 2p16.3 locus holding 7 suggestive single nucleotide polymorphisms (SNPs) within and downstream of LOC730100.
(B) Regional plot for the 2p16.3 locus. The 7 suggestive SNPs are in high linkage disequilibrium (LD) with each other but no other SNPs in the surrounding region. (C) Highlight of the
17q25.3 locus holding 7 suggestive SNPs across CEP131, ENTHD, and C17orf89. (D) Regional plot for the 17q25.3 locus. The 7 suggestive SNPs are in high LD with 5 further SNPs at this
locus identifying a 45.2 Kb long haplotype block. In regional plot, each circle represents a SNP, y-axis is the log10 association p value for frontotemporal dementia association and x-
axis represents the physical position on the chromosome (build 36, hg18). The circles are ﬁlled with colors according to the linkage disequilibrium (LD; r2) between the given SNP and
the lead SNP (purple square). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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Supplementary Fig. 3a and 3b) lending support to the idea that,
if on one hand the effect size of each single suggestive SNP is
rather small, on the other their cumulative effect on transcription
processes might be the biological mechanism underlying the as-
sociation at this locus.
3.1.2. Stratiﬁed analyses
We evaluated whether any SNP with 104 < p-value < 108
(Supplementary Table 1) differently associated with disease when
stratiﬁed by sex and the MAPT haplotypes.
Our analysis revealed that 2 SNPs, rs3110642 and rs3110643,
signiﬁcantly (p-values ¼ 0.022 and 0.027, respectively) associated
with FTD in the female population (Table 3). Both SNPs map to chr
17 and locate to the introns of the HNF1 homeobox B (HNF1B) gene;
of note, their OR is almost twice bigger in females comparatively to
men (OR ¼ 2.15 vs. 1.32 and OR ¼ 2.12 vs. 1.33; see Table 3).
The MAPT haplotypes were differently distributed in our cases
and controls (Table 4). Neither the H1/H1 nor the H1/H2 haplotype
combinations signiﬁcantly associated with disease, whereas H2/H2
was signiﬁcantly over-represented in the controls (p-value¼ 0.025;
OR ¼ 0.54) thus resulting protective (Table 4). We did not observe
any inﬂuence of any of the MAPT haplotypes on the suggestive or
nominally signiﬁcant SNPs, that is, the results observed in the as-
sociation analysis were independent from the MAPT haplotype
status.3.1.3. Analysis of candidate genetic markers
We then veriﬁed the relevance of other genetic risk factors that
have previously been associated with FTD and/or closely related
forms of neurodegenerative disease (Table 5).We ﬁrst evaluated the
SNPs in TMEM106B (Van Deerlin et al., 2010) and those identiﬁed in
the recent international FTD-GWAS for RAB38, CTSC, and the HLA
locus (Ferrari et al., 2014); then we assessed the markers deﬁning
the C9orf72 (van Es et al., 2009), MAPT (Höglinger et al., 2011), and
TOMM40/APOE (Seshadri et al., 2010) loci.
It is relevant to note that none of the international GWAS hits
(Ferrari et al., 2014; Van Deerlin et al., 2010) was replicated in the
Italian cohort reaching p values ofw3e5  101 and ORw1.04 for
the risk alleles of TMEM106B (Table 5), 6e7 101 and ORw1.05 for
the RAB38/CTSC risk alleles (Table 5) and 1e2  101 and OR w1.1
for the HLA locus risk markers (Table 5). When we assessed the
current suggestive SNPs in previous FTD-GWAS these held
nonsigniﬁcant p values (4e7  101; see Supplementary Table 4).
These data suggest that risk factors that associate with FTD cases
with European ancestry but of Western/Central/North-European
and North-American extraction seem not to associate with South-
European/Mediterranean population and (apparently) vice versa.
Similar results were obtained for the risk alleles at the C9orf72
(p-value ¼ 3  102, OR ¼ 1.2) and MAPT (p-value ¼ 7.57  101,
OR¼ 1.03; p-value¼ 4.77 102, OR¼ 1.2) loci (Table 5) suggesting
that these genetic risk factors seem not to associate with the Italian
FTD population.
Table 2
Haplotype analysis at the 17q25.3 locus
Locus Haplotype Frequency Frequency
FTD case
Frequency
controls
OR (95% CI) p Value
rs906175, rs2659030, rs9912789,
rs9896850, rs2725391, rs9319617, rs12939525,
rs8073077, rs969413, rs1048775, rs2255166, rs2659005
(1) CGTTCCCTTGTC 0.43 0.39 0.49 0.695 (0.59e0.82) 7.42  106
(2) TACCTTTCACCT 0.43 0.52 0.42 1.42 (1.20e1.65) 1.60  105
(3) CGCCCCTCTGTC 0.02 0.02 0.03 0.71 (0.41e1.23) 21.7  101
(4) TACCTTTCACCC 0.02 0.03 0.02 1.35 (0.79e2.31) 2.92  101
(5) TACCTTTCACTT 0.02 0.02 0.02 1.31 (0.71e2.40) 3.83  101
(6) CGCCCTTCTGTC 0.02 0.03 0.02 1.005 (0.77e1.32) 9.73  102
rs906175,rs2659030, rs2725391,
rs969413, rs1048775, rs9319617, rs2255166
(1) CGCTGCT 0.47 0.42 0.52 0.67 (0.58e0.79) 8.30  107
(2) TATACTC 0.45 0.53 0.43 1.45 (1.23e1.69) 4.39  106
(3) CGCACCC 0.01 0.01 0.01 0.56 (0.25e1.24) 1.50  101
(4) TATACTT 0.02 0.02 0.02 1.37 (0.77e2.40) 2.86  101
(5) CGCTGTT 0.02 0.02 0.02 0.92 (0.55e1.55) 7.56  101
Logistic regression results for haplotypes constructed using 12 and 7 SNPs mapping to the long arm of chr 17 (17q25.3 locus), adjusting for sex and the ﬁrst 4 principal
components. For each haplotype, we reported the frequency in FTD cases and controls.
Key: CI, conﬁdence interval; FTD, frontotemporal dementia; OR, odds ratio; SNPs, single nucleotide polymorphisms.
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p-value ¼ 2.1  105 and OR ¼ 1.65 (Table 5) implying that either
this locus might be suggestive for the Italian FTD population or that
there is an underlying presence of AD cases within our FTD cohort.
Keeping in mind that it had been previously shown that APOE ge-
notypes and/or alleles revealed variable associations either with
longevity or disability in the Italian population (Bader et al., 1998;
Benedetti et al., 2002; Scacchi et al., 1995), we carried forward the
analysis of other typical AD genome-wide markers in our study
cohort to further investigate the potential presence of AD among
the FTD cases; particularly, we analyzed 5 other loci/SNPs that have
consistently been associated with AD such as: rs157580 (TOMM40/
APOE), rs11136000 (CLU), rs3818361 (CR1), rs3851179 (PICALM), and
rs744373 (BIN1) (Harold et al., 2009; Hollingworth et al., 2011;
Lambert et al., 2009). Our analysis revealed that none of the
markers associated with our study population (p-value w101;
Table 5) suggesting that most probably the risk of a contamination
of AD cases within our FTD cohort is likely to be minimal.
3.2. SNPs-to-genes analysis
To identify genes associated with disease and to replicate the
results of our association analysis, we performed GATES, sPCA, and
SKAT analyses. Genes with p-value < 0.05 after FDR correction are
displayed in Fig. 3, Table 6 and described here in the following
sections.
3.2.1. GATES analysis
The genes with lowest p values were CEP131, ENTHD2, and
C17orf89 (Table 6), supporting them as suggestive candidates as per
association analysis (Table 1). Additional 11 genes resulted signiﬁ-
cant (Table 6): thesewere all among the nominally signiﬁcant genes
as per association analysis (Supplementary Table 1). Of note, HNF1B
that we showed above being a potential sex-speciﬁc disease-asso-
ciated marker (Table 3) was among these 11 genes (Table 6).
3.2.2. sPCA analysis
The sPCA analysis revealed 30 signiﬁcant genes the ﬁrst 2 being
CEP131 and ENTHD2 (supporting the results of the association and
the GATES analyses) (Table 6). Comparing the sPCA results with
those obtained through GATES, a total of 7 genes (CEP131, ENTHD2,
TOMM40, HNF1B, PVRL2, SAMD12, and C9orf150) were signiﬁcant
(and conﬁrmed by both methods).
3.2.3. SKAT analysis
The SKAT analysis revealed 4 signiﬁcant genes (CEP131, ENTHD2,
C17orf89, and QPCT) (Table 6). QPCT was neither in the output ofGATES or sPCA nor the association analyses (Table 6 and
Supplementary Table 1). SKAT analysis conﬁrmed CEP131, ENTHD2,
and C17orf89 being signiﬁcant as per GATES and association
analyses.
Taken all together, the 3 analyses (GATES, sPCA, and SKAT)
revealed the following: (1) all the signiﬁcant genes after GATES
analysis (CEP131, ENTHD2, C17orf89, TOMM40, HNF1B, ZCCHC24,
PVRL2, SLC38A10, CCDC12, SAMD12, GYPC, KLHL18, RSU1, and
C9orf150), belonged to the group of suggestive or nominally sig-
niﬁcant genes as per association analysis (Table 1 and
Suuplementary Table 1); (2) 2 genes (CEP131 and ENTHD2) were
consistently identiﬁed across the 3 analysis methods (GATES, sPCA,
or SKAT) and belonged to the strongly suggestive hits as per asso-
ciation analysis (Table 1); (3) a number of further genes were
shared across the GATES and sPCA methods (TOMM40, HNF1B,
PVRL2, SAMD12, and C9orf50), and the GATES and SKAT methods
(C17orf89); and (4) a number of genes were unique to each method
of analysis: (i) ZCCHC24, SLC38A10, CCDC12, GYPC, KLHL18, and RSU1
for the GATES method; (ii) PRKG1, DNAJA4, CNTN4, MYO10, SGCG,
LPAR3, FOXK2, NAP5, TMEM169, TTLL9,MUSK, SP100, SCGB1D4, IRF8,
LARGE, PLCB3, CDKN3, RASGRF1, IL1RL1, CCDC81, WDR45L, PTGER3,
and MDGA2 for the sPCA method; and (iii) QPCT for the more
conservative SKAT method.
In summary, after the SNPs-to-genes analyses, we conﬁrmed the
relevance of the locus on chr 17 (17q25.3), which was shown to be
strongly suggestive after association analysis (Table 1). Of note, we
did not consistently identify the locus on chr2, 2p16.3, among the
signiﬁcant genes/loci through our SNPs-to-genes analyses as after
multiple test corrections for GATES, sPCA, and SKAT no association
was evident. This may be due to the fact that because the SNPs-to-
genes analyses assessed 2087 SNPs at this locus (2p16.3) and the
suggestive SNPs (n¼ 7) are in strong LD exclusively with each other
(see Fig. 2B), this locus was not powerful enough to identify an
association. Nevertheless, the suggestive p values of the association
analysis and the OR of 2.5e2.8 (Table 1) indicate that this locus will
beneﬁt from further investigation to gather on its actual role in this
population. In total, we identiﬁed 8 genes (CEP131, ENTHD2,
C17orf89, TOMM40,HNF1B, PVRL2, SAMD12, and C9orf150) that were
suggestive in the association analysis (Table 1 and Supplementary
Table 1) and supported by the SNPs-to-genes analysis (Table 6).
3.3. GO terms analysis
After having identiﬁed a number of DAGs through our associa-
tion and SNPs-to-genes analyses, we intended to better charac-
terize their functional and biological relevance. Thus, we performed
a GO analysis based on a list of 280 DAGs (271 and 9 nonoverlapping
Table 3
Gender stratiﬁed analysis
SNP p-Value females OR (CI 95%) females p-Value males OR (CI 95%) males p-Value int OR (CI 95%) int Coded allele Gene Function
rs3110642 3.11  106 2.15 (1.56e2.96) 5.80  102 1.32 (0.99e1.76) 0.022 1.62 (1.08e2.53) C HNF1B Intron
rs3110643 4.55  106 2.12 (1.54e2.92) 5.24  102 1.33 (0.997e1.78) 0.027 1.59 (1.05e2.50) C HNF1B Intron
rs3110648 1.51  105 1.96 (1.44e2.65) 2.18  102 1.38 (1.05e1.82) 0.077 1.42 (0.96e2.17) G HNF1B Intron
rs9912789 2.25  105 0.61 (0.48e0.77) 8.02  103 0.74 (0.59e0.92) 0.259 0.83 (0.60e1.15) T CEP131 Intron
rs2659030 3.41  105 1.61 (1.29e2.02) 2.76  103 1.41 (1.13e1.78) 0.451 1.14 (0.82e1.54) A CEP131 Intron
rs906175 3.43  105 1.61 (1.29e2.02) 3.96  104 1.51 (1.20e1.89) 0.728 1.07 (0.77e1.45) T CEP131 Intron
rs9319617 4.16  105 0.62 (0.50e0.78) 1.80  103 0.70 (0.56e0.89) 0.501 0.89 (0.65e1.23) C CEP131 Intron
rs9896850 7.56  105 0.63 (0.50e0.79) 2.36  103 0.70 (0.56e0.88) 0.519 0.89 (0.65e1.24) T CEP131 Intron
We reported the logistic regression results for females (n ¼ 637) and for males (n ¼ 821) and the gender  SNP interaction analysis for the total sample (n ¼ 1458) with odds
ratio (OR) ¼ OR (female)/OR (male). For each SNP, we reported the coded allele associated to odds ratio and the relative mapped gene and function.
Key: CI, conﬁdence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
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tively; Supplementary Table 5 and Supplementary Fig. 4) specif-
ically looking at how functionally similar GO terms clustered and
which were most signiﬁcant among each category (BP, CC, and MF).
3.3.1. Functional annotation clustering
After the ES (threshold 1.3) was calculated for each functional
annotation cluster, 3 were found signiﬁcant with ES of 2.1, 1.8, and
1.7 (Supplementary Table 6 and Supplementary Fig. 5a).
The ﬁrst cluster (ES ¼ 2.1) includes 37 GO terms. Fourteen of 37
are speciﬁc to the brain, particularly, to processes such as brain
development, neuronal genesis, maturation and differentiation,
and axonogenesis. The remainder terms are more general and point
to system development, cell differentiation and projection, as well
as cell-cell adhesion. This cluster suggests that our DAGs are
involved in systems’ development and differentiation into mature
structures and it is relevant to note that a robust association with
the brain was evident considering the identiﬁcation of processes
related to the development and maturation of neurons and the
formation of axons (Supplementary Fig. 5b).
The second cluster (ES ¼ 1.8) includes only 7 GO terms. This
cluster reveals enrichment, in general, of genes pointing toward
elements of the plasma membrane with receptor-like activity
(Supplementary Table 6).
The third cluster (ES ¼ 1.7) includes up to 10 GO terms. It is of
relevance that this cluster reveals an enrichment of genes whose
products localize to the synapse regulating neurotransmission and
plasticity (Supplementary Fig. 5a and 5c).
To support DAVID results a gene-set enrichment analysis for
each GO category (BP, CC, and MF) was performed on the totality of
the annotated genes ranked by the lowest p value from either the
GATES, sPCA, or SKAT analysis.
3.3.2. TopGO BP
Considering a minimum of 8 genes to support a GO term
enrichment and a signiﬁcance Kolmogorov-Smirnov p value for theTable 4
Case and/or control MAPT haplotype association analysis
MAPT haplotypea FTD (n ¼ 516) Controls (n ¼ 909) OR (95% CI) p Value
H1/H1 302 (58.5%) 503 (55.3%) 1.20 (0.96e1.51) 0.107
H1/H2 194 (37.1%) 349 (38.4%) 0.93 (0.74e1.18) 0.566
H2/H2 29 (3.90%) 57 (6.30%) 0.54 (0.32e0.92) 0.025
For eachMAPT haplotype, we reported the frequencies (numbers and %) in FTD cases
and controls. In both analyses, the logistic regressions are corrected for sex and the
ﬁrst 4 principal components.
Key: CI, conﬁdence interval; FTD, frontotemporal dementia, MAPT, microtubule-
associated protein tau.
a Sixteen cases and 17 controls had missing values.“weight01” analysis starting at p-value < 0.01, up to 87 GO terms
resulted signiﬁcant for the BP ontology (Supplementary Table 7).
The signiﬁcant terms can be subdivided in 3 groups based on 3
different p-value cutoffs. In group 1 (p-value < 0.001), there was a
total of 16 terms of which 6 directly related to the brain (“synaptic
transmission,” “central nervous system development,” “synaptic
transmission, glutamatergic,” “dendrite morphogenesis,” “regula-
tion of synaptic transmission, glutamatergic,” and “positive regu-
lation of synaptic transmission, glutamatergic”) replicating the
group of BPs highlighted by the third cluster of the DAVID analysis
(Supplementary Table 6). There were 3 additional terms related to
ion transmembrane transport and “cellular response to epineph-
rine stimulus,” all suggesting an involvement in neurotransmission
processes. In group 2 (0.001 < p-value < 0.005), there were 40 GO
terms of which 5 directly related to the brain (“striatum develop-
ment,” “axon guidance,” “long-term synaptic potentiation,”
“learning,” and “forebrain neuron differentiation”) and replicated
the ﬁrst cluster of the DAVID analysis (Supplementary Table 6); also,
9 further GO terms here supported the membrane potential regu-
lation process (Supplementary Table 7). Finally, group 3 (0.01 < p-
value < 0.005) revealed 31 GO terms, 5 of which directly related to
the brain (“hypothalamus development,” “negative regulation of
axon extension involved in axon guidance,” “regulation of glial cell
proliferation,” “cognition,” and “neuron cell-cell adhesion”) and
replicated the DAVID analysis results of both clusters 1 and 3
(Supplementary Table 6); in addition, 6 GO terms indicated ion
transmembrane transport and 2 regulation of immune response
activity (Supplementary Table 7).
3.3.3. TopGO CC
The CC ontology analysis revealed a number of relevant GO
terms for each of the 3 groups as per p-value cutoff. In group 1, there
was a total of 9 GO terms of which 5 (“postsynaptic membrane,”
“presynaptic membrane,” “postsynaptic density,” “synapse,” and
“dendrite”) directly related to neurotransmission processes and 1
to the “glutamate receptor complex” (Supplementary Table 7).
In group 2, there was a total of 9 GO terms 3 of which directly
related to the neurons including the “presynaptic active zone” and
the “axon” and 2 indicated, respectively, the “voltage-gated calcium
channel complex” and the “receptor complex” (Supplementary
Table 7). Finally, in group 3 there was a total of 10 GO terms that
included the “voltage-gated potassium channel complex,” the
“dendritic spine,” and the “MHC class II protein complex”, implying
to synaptic transmission and an involvement of transmembrane
elements and the immune system (Supplementary Table 7). In
summary, this analysis reveals a strong implication of processes
happening at the level of the synapsis including neurotransmission
in general and at the level of the dendritic spine, resulting sup-
portive of the previous Section 3.3.2 and replicating the third
cluster of the DAVID analysis (Supplementary Table 6).
Table 5
Genome-wide association results for published SNPs in FTD and other neurodegenerative diseases
Gene Minor allele Major allele Frequency of minor allele OR of minor allele (95% CI) p Value Imputation quality
Markera
rs1990622 TMEM106B G A 0.39 0.92 (0.78e1.08) 3.19  101 0.100
rs6966915 TMEM106B T C 0.39 0.93 (0.79e1.09) 3.73  101 0.998
rs1020004 TMEM106B C T 0.28 0.95 (0.80e1.14) 5.96  101 0.999
rs302652 RAB38 A T 0.25 0.97 (0.81e1.16) 7.26  101 0.975
rs16913634 RAB38/CTSC A G 0.11 1.07 (0.82e1.38) 6.23  101 0.882
rs9268877 HLA-DRA/HLA-DRB5 A G 0.42 0.91 (0.77e1.07) 2.54  101 0.987
rs9268856 HLA-DRA/HLA-DRB5 A C 0.19 0.87 (0.71e1.07) 1.82  101 0.988
rs1980493 BTNL2 C T 0.10 0.82 (0.60e1.11) 1.97  101 0.901
rs3849942 C9orf72/MOB3B T C 0.29 1.21 (1.02e1.43) 3.00  102 1.000
rs242557 MAPT A G 0.33 1.03 (0.87e1.22) 7.57  101 0.995
rs8070723 MAPT G A 0.25 0.83 (0.69e1.00) 4.77  102 0.999
rs2075650 TOMM40/APOE G A 0.12 1.65 (1.31e2.08) 2.10  105 0.996
Markerb
rs157580 TOMM40/APOE G A 0.39 0.87 (0.74e1.02) 9.17  102 0.993
rs11136000 CLU T C 0.35 0.86 (0.68e1.08) 1.94  101 0.502
rs3818361 CR1 A G 0.20 1.01 (0.83e1.23) 9.47  101 0.997
rs3851179 PICALM T C 0.37 1.00 (0.85e1.18) 9.93  101 0.998
rs744373 BIN1 G A 0.28 0.97 (0.81e1.15) 6.98  101 0.986
Key: AD, Alzheimer’s disease; ALS; amyotrophic lateral sclerosis; FTD, frontotemporal dementia; GWAS; genome-wide association studies; SNP, single-nucleotide
polymorphism.
a Results for SNPs associated with FTD (TMEM106B, RAB38 and CTSC, HLA-DRA/DRB5 and BTNL2); FTD-ALS (C9orf72/MOB3B); FTD-17 (MAPT), and AD (TOMM40/APOE).
b Analysis for AD-speciﬁc loci highlighted by major AD-GWAS. We reported the results of the logistic regression under an additive model on SNP dosage levels adjusting for
sex and the ﬁrst 4 principal components. To retrieve information about SNPs and their genomic context (the nearest gene), we used the hg18 (NCBI 36) assembly.
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Further, the MF ontology analysis highlighted several signiﬁcant
GO terms (encompassing groups 1e3). In this respect, the main
outcome here is the indication of the process of neurotransmission
through terms such as “calmodulin binding,” “ion channel binding,”
“ionotropic glutamate receptor activity,” “glutamate receptor
binding,” “high voltage-gated calcium channel activity,” “extracel-
lular-glutamate-gated ion channel,” “voltage-gated potassium
channel activity,” and “voltage-gated calcium channel activity”
(Supplementary Table 7). These results critically highlight that
these enrichments are cross-supportive within the MF analysis as
well as across the other ontology terms (BP and CC) and all clusters
of the DAVID analysis (Supplementary Table 6). As a matter of fact,
we see here that activities which imply neuronal membrane
receptors, signaling transduction and propagation of electrical
signal at the level of the synapses are signiﬁcantly enriched
(Supplementary Table 7).Fig. 3. SNPs-to-genes analysis. The Venn diagram shows the number of genes that
were signiﬁcant after FDR correction (p-value < 0.05) and their level of overlap across
the 3 methods (GATES, sPCA, and SKAT). Abbreviations: FDR, false discovery rate;
GATES, extended Simes’ procedure; SKAT, sequential kernel machine association test;
sPCA, supervised principal components analysis.4. Discussion
To the best of our knowledge, this is the ﬁrst comprehensive
genome-wide study on Italian FTD. We performed a classical as-
sociation analysis and thenwe further characterized our data set by
means of an innovative 3-fold statistical approach that uses p values
(from the association analysis) or directly the genotyping data to
identify genes associated with disease.
Seven SNPs at the 2p16.3 locus were suggestive and the risk
alleles showed high OR (>2.5). These SNPs map to the LOC730100
gene, a long noncoding RNA. Long noncoding RNAs are elements
implicated in a number of complex processes that include chro-
matin stabilization, histone methylation as well as pretranscrip-
tional and post-transcriptional (cis- and trans-) regulation
(Mercer et al., 2009). We could not identify a potential disease-
associated haplotype at this locus, neither could we verify any
effects on transcription in cis for the suggestive SNPs nor were
these in LD with any SNP locating to neighboring genes. However,
this locus seems to hold importance due to the 2-fold OR value as
per association analysis and the vicinity of the NRXN1 gene. The
latter is involved in neurodevelopment and has been shown to
carry pathogenic CNVs associated with a spectrum of neuro-
behavioral and neuropsychiatric disorders (Bena et al., 2013); as
such, it cannot currently be fully dismissed as a possible biological
reason for association at this locus. We thus suggest that NRXN1
should be investigated for variability including single nucleotide
variants, indels, and CNVs to shed light on its potential role in
(Italian) FTD.
Seven SNPs at the 17q25.3locus showed suggestive association
with OR > 1.5 for each risk alleles. These SNPs map to 3 genes:
CEP131, ENTHD2, and C17orf89. CEP131 encodes a centrosomal
protein of 131 kDa weight, which is part of the centrosomal com-
plex and seems involved in cilia formation and genome stability
processes (Staples et al., 2012). ENTHD2 encodes a protein that lo-
calizes to the cytoplasm and seems to be involved in trans-Golgi
network vesicular processes (Borner et al., 2012), whereas
C17orf89 is still uncharacterized. Based on this information it is
difﬁcult to diagnose a direct impact of these 3 genes on the biology
Table 6
SNPs-to-genes analysis
Type of analysis Gene Chromosome No. snps No. noprun p Value p(B&H)
GATES CEP131 17 35 19 8.71  108 0.001469158
ENTHD2 17 3 3 6.19  107 0.004264162
C17orf89 17 3 3 7.59  107 0.004264162
TOMM40 19 7 7 2.61  106 0.010990904
HNF1B 17 49 44 3.86  106 0.013022048
ZCCHC24 10 71 65 7.17  106 0.020079536
PVRL2 19 35 27 8.33  106 0.020079536
SLC38A10 17 45 39 1.30  105 0.026345165
CCDC12 3 24 21 1.41  105 0.026345165
SAMD12 8 561 448 1.66  105 0.028043171
GYPC 2 82 75 2.69  105 0.039120914
KLHL18 3 22 22 2.78  105 0.039120914
RSU1 10 261 202 3.04  105 0.039225533
C9orf150 9 58 50 3.26  105 0.039225533
sPCA CEP131 17 35 5 4.11  108 0.000649963
ENTHD2 17 3 2 1.43  107 0.001006946
PRKG1 10 1454 226 1.91  107 0.001006946
PVRL2 19 35 7 6.85  107 0.002710751
C9orf150 9 58 10 2.92  106 0.009232674
DNAJA4 15 22 4 3.55  106 0.009367238
CNTN4 3 1300 342 4.56  106 0.010301712
HNF1B 17 49 12 5.44  106 0.010760416
TOMM40 19 7 2 7.21  106 0.012686542
MYO10 5 287 54 8.66  106 0.013705096
SGCG 13 262 34 1.67  105 0.022891771
LPAR3 1 85 16 1.74  105 0.022891771
FOXK2 17 55 10 2.08  105 0.024754692
NAP5 2 827 129 2.19  105 0.024754692
TMEM169 2 24 6 2.66  105 0.028034957
TTLL9 20 45 9 2.92  105 0.028884881
MUSK 9 136 24 3.17  105 0.029550084
SP100 2 160 50 3.53  105 0.031011342
SCGB1D4 11 13 3 4.62  105 0.038479061
IRF8 16 69 11 5.20  105 0.041181866
LARGE 22 831 169 6.02  105 0.045098118
PLCB3 11 8 2 6.40  105 0.045098118
CDKN3 14 16 5 6.65  105 0.045098118
RASGRF1 15 115 24 6.84  105 0.045098118
IL1RL1 2 83 15 8.17  105 0.047840935
CCDC81 11 76 14 8.29  105 0.047840935
WDR45L 17 41 9 8.34  105 0.047840935
PTGER3 1 193 35 8.46  105 0.047840935
MDGA2 14 933 168 8.88  105 0.048410287
SAMD12 8 561 78 9.17  105 0.048410287
SKAT CEP131 17 35 35 8.35  1010 0.000014
ENTHD2 17 3 3 1.05  107 0.000651
C17orf89 17 3 3 1.15  107 0.000651
QPCT 2 34 34 2.39  106 0.010138
Genes with p-value < 0.05 after FDR correction by GATES, sPCA, and SKAT methods.
Key: FDR, false discovery rate; GATES, extended Simes’ procedure; No. noprun, number of SNPs not pruning by the method; No. snps, number of SNPs cover by gene; p(B&H), p
value after FDR correction with the Benjamini & Hochberg procedure; p value, raw p value; SKAT, sequential kernel machine association test; sPCA, supervised principal
component analysis.
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ENTHD2, and C17orf89) have consistently been replicated in our
SNPs-to-genes analysis by either method (GATES, sPCA, and SKAT),
but also there are a number of reasons to consider the association at
this locus of potential biological relevance. First, we veriﬁed that the
7 risk alleles of the suggestive SNPs deﬁne a haplotype substructure
that signiﬁcantly associated with disease status with an OR ¼ 1.45,
and second, each of the risk alleles had signiﬁcant or suggestive
effects on transcription, speciﬁcally, causing a decrease of expres-
sion of cis genes such as RFNG, AATK, andMIR1250. RFNG encodes an
N-acetylglucosaminyltransferase for which involvement in neuro-
genesis and a role in modulating Notch signaling has been previ-
ously suggested (Mikami et al., 2001). AATK was shown to have a
potential role in apoptotic processes inmature neurons (Baker et al.,
2001), and even more interestingly, in neuronal differentiation
(Baker et al., 2001) or axon outgrowth (Takano et al., 2012).
Conversely, a general implication in regulation of transcription and/or gene expression applies to MIR1250. Taken together our results
suggest that neuronal development, maturation, and axonogenesis,
as well as regulation of gene expression might be impacted in the
Italian FTD population.
Whenwe tested for association based on gender, we identiﬁed 2
SNPs mapping to the HNF1B gene being signiﬁcant in the female
FTD population. HNF1B encodes a member of the homeodomain-
containing family of transcription factors. The product of this
gene is expressed in the brain; however, any potential role in the
brain has not been described thus far. Rather, HNF1B has been
suggested being involved in ovarian adenocarcinoma (DeLair et al.,
2013; Shen et al., 2013) and renal failure (Musetti et al., 2014).
Nevertheless, of particular interest is the fact that variability in this
gene seems speciﬁcally to associate with conditions affecting
women as shown in the current and other studies (DeLair et al.,
2013; Shen et al., 2013). All the more, it is relevant to note that
this gene is involved in regulation of transcription likewise the
R. Ferrari et al. / Neurobiology of Aging 36 (2015) 2904.e13e2904.e262904.e23LOC730100 and the MIR1250 genes, suggesting that regulation of
gene expression needs to be considered and further investigated to
shed light on its potential contribution to disease etiology.
When we assessed the loci that had previously been associated
with FTD, we did not replicate the top SNPs for FTD with TDP-43
pathology (Van Deerlin et al., 2010) neither those as per the inter-
national GWAS (Ferrari et al., 2014). This may be due to the fact that,
besides the European ancestry, the Mediterranean population
might not exactly share the same risk factors as that of Western/
Central/North- and American-European extraction. Of note, also the
other candidate loci including MAPT and C9orf72 resulted nonsig-
niﬁcant. Particularly, concerning MAPT, we also assessed any po-
tential implication of theMAPT haplotype in our cohort: we veriﬁed
that the H1 haplotype did not associate with disease, whereas the
H2 haplotype resulted protective, and that the results of our asso-
ciation analysis were independent from the MAPT haplotype. Hav-
ing identiﬁed TOMM40 and PVRL2 among the signiﬁcant genes
through the SNPs-to-genes analysis, and keeping inmind that these
reached nominal signiﬁcance in our association analysis this in-
dicates that APOE, notably an AD locus, needed attention. Whenwe
veriﬁed association for loci speciﬁc to other neurodegenerative
diseases, we identiﬁed the TOMM40/APOE locus reaching p value of
2.1  105 (rs2075650; OR ¼ 1.65) in our FTD cohort. However,
when we evaluated other AD-GWAS markers for TOMM40/APOE,
CLU, CR1, PICALM, and BIN1 there was no association at all. If on one
hand we cannot fully exclude a minimal presence of AD cases
within our FTD clinical cohort, on the other there is also evidence in
the literature of an independent association of the APOE locus with
FTD, especially involving the APOE E4 allele (Stevens et al., 1997).
This seems to occur also in Italian FTD cases (Rubino et al., 2013;
Seripa et al., 2011, 2012). Particularly, a genetic study showed that
APOE E4 associated with FTDwith OR¼ 2.26 and, as well, variability
in TOMM40 held an APOE E4-dependant association with Italian
FTD, with OR ¼ 2.11 (Bagnoli et al., 2013). Also, an imaging based
study showed that the APOE E4 allele underlies higher brain
vulnerability not only in AD but also in FTD and that other
concomitant genetic and/or environmental factor(s) might modu-
late the detrimental effects of APOE E4 leading to the different
regional vulnerability that is at the basis of the topographical dif-
ferences in the affected areas in AD (mediotemporal) and FTD
(frontotemporal) (Boccardi et al., 2004). Taken all this together and
based on our own data, APOE might be a locus to be further char-
acterized in the Italian FTD population, and conversely, the risk of a
contamination of AD cases within our study cohort, if any, is likely
to be minimal.
The classical association analysis was followed by the SNPs-to-
genes analysis, an innovative 3-fold statistical approach that uses
p values (from the association analysis) or directly the genotyping
data to identify genes associated with disease. The SNPs-to-genes
approach not only is a method to replicate and/or support the re-
sults of the association analysis but also provides further insight
into the genetics of this disease with a particular focus on genes.
This is important because it allows to direct our attention on gene
products that can then be taken forward into functional annotation
analysis to interpret more comprehensively their biological rele-
vance and to shed light on the biological and/or molecular pro-
cesses and cellular compartments that might be impacted and
inﬂuence disease pathogenesis.
Our SNPs-to-genes results, through 3 different methods (GATES,
sPCA, and SKAT), supported the data of the association analysis,
particularly indicating the 17q25.3 locus as a potential novel locus
for the Italian FTD population. These analyses were supportive of
the association analysis and contributed to enlarge the list of genes
potentially relevant to FTD in the Italian population. We observed
that 8 genes indicated by our association analysis were signiﬁcantlyreplicated by any of the 3 methods (GATES, sPCA, and SKAT):
CEP131, ENTHD2, C17orf89, TOMM40, HNF1B, PVRL2, SAMD12, and
C9orf150. If we have already commented on the ﬁrst 6 genes of this
list, not much can currently be said about the remaining 2 as both,
the sterile alpha motif domain containing 12 (SAMD12) and the
C9orf150 (or leucine rich adaptor protein 1-like [LURAP1L]) genes
have not yet been fully characterized, thus it is currently difﬁcult to
assess their potential relevance in FTD. All the more, the GATES,
sPCA, and SKAT methods identiﬁed an overall list of genes sug-
gestive for association with disease (DAGs) in our cohort that we
decided to investigate more in depth for their biological meaning
and potential implication in the biology of the brain and FTD. In this
respect, our enrichment analysis based on an input of 280 genes
(derived from the association and the SNPs-to-genes analyses),
interestingly indicated that a number of our DAGs are, in fact,
implicated in the biology of the brain. Speciﬁcally, they revealed
that elements regulating neuronal maturation, axonal formation
and synapse plasticity, as well as presynaptic and postsynaptic
activities (involving neurotransmission), might play a role in the
neurobiology of FTD in the Italian population. Of particular interest
is the fact that we veriﬁed that the risk alleles at the 17q25.3 locus
exert an effect on expression, that is, a decrease in expression of cis
genes that, in fact, are involved in processes highlighted by our GO
terms analysis such as neuronal development, differentiation and
maturation, and axonogenesis. All the more, the 2p16.3 locus
comprises the NRXN1 gene that also is involved in neuro-
development. These data are of interest in that our association and
GO terms analysis seem cross-supportive to the extent that they
suggest that common mechanisms involving the biology of the
neurons and that of the synapses might be implicated in the
pathogenesis of FTD in the Italian population. Finally, the enrich-
ment analysis also suggested that processes involving regulation of
immune response and MHC class II molecules (and most probably
microglial cells) require further study and characterization in the
Italian FTD population.
5. Conclusions
In summary, the following can be gathered from our study: (1)
this is the ﬁrst genetic study of this size in the Italian FTD popula-
tion; (2) we identiﬁed 2 novel potential loci for FTD; (3) one of the 2
new loci (17q25.3) revealed the existence of a haplotype sub-
structure that signiﬁcantly associates with disease and likely exerts
its effect by affecting expression (decrease) of nearby cis genes; (4)
our association analysis results for the 17q25.3 locus were sup-
ported by additional SNPs-to-genes analyses performed and vali-
dated bymeans of 3 different statistical methods (GATES, sPCA, and
SKAT); (5) genes directly or indirectly highlighted by our analyses,
such as NRXN1, RFNG, and AATK, are involved in neuronal devel-
opment, differentiation and maturation, and axonogenesis pro-
cesses; (6) our enrichment analyses supported these biological
functions revealing signiﬁcant GO terms that included elements
pointing to the biology of the brain, particularly, neurogenesis,
neuronal development, differentiation and maturation, as well as
the biology of the synapse, including neurotransmission, synapse
plasticity, and membrane potential modulation; and (7) our GO
terms analysis also showed a potential involvement of microglial
cells, thus neuronal pruning (which is part of the process of neurons
maturation) and functional brain connectivity (Zhan et al., 2014), as
well as an overall involvement of regulation of immune response.
Although we need to be cautious about any speculation at present
because we did not replicate the same genetic loci, the latter point
is of relevance as it might indirectly support the outcome of our
international GWAS about an involvement of the immune system in
the neurobiology of FTD (Ferrari et al., 2014).
R. Ferrari et al. / Neurobiology of Aging 36 (2015) 2904.e13e2904.e26 2904.e24Our study is clearly not conclusive and requires the identiﬁed
loci and genes to be further studied and replicated especially to
discriminate those markers and genes that likely drive the associ-
ations and are involved in the susceptible molecular mechanisms
potentially at play in the process of pathogenesis of FTD in the
Italian population.
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